Clinicopathological Characteristics and Survival Outcomes of Primary Signet Ring Cell Carcinoma of the Prostate: A SEER-Based Study

X. Gu,X. S. Gao
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.1168
2017-01-01
Abstract:Primary signet ring cell carcinoma (SRCC) of the prostate is an exceedingly rare disease. We aimed to investigate the clinicopathological characteristics and survival outcomes of primary SRCC of the prostate. Data were requested from Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 2013. Patients of interest were identified by site recode C61.9 (prostate) and ICD-0-3 code 8490/3 (SRCC) from SEER. The primary endpoint was cancer specific survival (CSS) and the secondary endpoint was overall survival (OS). The last follow-up was up to December 31, 2013. Because the SEER dataset consists of de-identified secondary data for research purposes, this study was exempt from full review by the institutional review board. Our analyses were adjusted for age, sex, race (white, black, and other), year of diagnosis, treatment with surgery, treatment with radiation, AJCC T stage, AJCC N stage, AJCC M stage, and tumor grade. CSS and OS analyses were performed using the Kaplan-Meier method. The log-rank test was used to compare the survival difference. Cox proportional hazards models was used to calculate multivariable-adjusted hazard ratios (HRs) and associated 95% confidence intervals (CIs). The statistical analyses were conducted using the SPSS 22.0 software. A two sided p value < 0.05 was regarded statistically significant. A total of 153 patients with primary SRCC of the prostate were included. The median age was 68 years. The mean survival time (MST) of CSS and OS were 185.9 months (95% CI= 160-211.8) and 118.4 months (95%CI= 99-137.8), respectively. The 5-year, 10-year, and 15-year survival rate were 84.3%, 68% and 54.2% for CSS and were 65.7%, 40.5%, and 25.6% for OS, respectively. CSS was not significantly different between patients treated with surgery (yes vs no, p=0.149) or treated with radiation (yes vs no, p=0.139). OS was not significantly different between patients treated with surgery (yes vs no, p=0.669), but differed significantly between patients treated with radiation (yes vs no, p=0.048). Multivariable analysis showed that treatment of either of surgery or radiation was associated with better CSS and OS compared with observation. Primary SRCC of the prostate has unique clinicopathological characteristics. Treatment of radiation could improve OS. Treatment of either surgery or radiation was associated with longer CSS and OS. Aggressive treatment of surgery or radiation should be recommended for this patient group in clinical management.
What problem does this paper attempt to address?